01 abril 2023

AMGEN ACTUALIZA A Phase 2 Study of TARLATAMAB in Patients With Recurrent Small Cell Lung Cancer (SCLC) (DeLLphi-301) .


Tarlatamab, a First-In-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small Cell Lung Cancer .


Tarlatamab/ AMGEN . (Byma. .z  Bispecific T Cell Engager, BiTE®) in Small Cell Lung Cancer ( DeLLphi-301 ) @JSMO_Official By Dr. Hiroki Izumi.


 Tarlatamab Binds DLL3 And CD3 Leading To T Cell Mediated Tumor Lysis. 


ORR 23% And PFS 3.7% in Heavily Pretreated SCLC .